- Email: [email protected]
The treatment of inflammatory breast carcinoma by radiation
moist desquamation; soft tissue necrosis did not occur. These results demonstrate that the first Course of irradiation did not select for a clone of radiation therapy may have much to offer in controlling locally recurrent breast cancer.
(30)
THE TREATMENT OF INFLAMMATORY BREAST CARCINOMA BY RADIATION Ann M. Chu, M.D., Dept. of Radiation Medicine, Massachusetts General Hospital, Boston, Mass. William Wood, M.D., Dept. of Surgery, Massachusetts General Hospital , Boston, Mass. Joanne Doucette, B.A., Dept. of Radiation Medicine, Massachusetts General Hospital, Boston, Mass.
From January 1958 through December, 1975, 47 patients with clinical inflammatory breast carcinoma were treated with radiation at the Massachusetts General Hospital. Study includes only those patients who had cliniForty cally local disease confined to the breast and peripheral lymphatics. patients are dead of their disease indicative of the fulminating nature of this tumor. The median survival is 17 months (range 1 month to 8 years, 9 months). Twenty-eight of 47 patients developed local recurrence within the irradiated breast. There does appear to be a definite correlation between dose delivered and local control in this study. An analysis of local recurrence rate as a function of dose (TDF), dosimetry, field arrangements and equipment used will be analyzed. The prognosticating role of extent of erythema, presence or absence of axillary or supraclavicular lymph nodes on survival will be correlated. The effect of hormonal ablative procedures, hormonal manipulation or chemotherapy will be discussed. As survival is determined by high instance of metastatic disease, the combination of effective local treatment and adjuvant multi-agent chemotherapy may hold promise for improving the poor survival seen in this group of patients. Recommendations for an altered radiation regimen, e.g. ultrafractionation will be proposed.
(31) PRIMARY IRRADIATION THERAPY AS M4NAGEMENT FOR STAGE I AND STAGE II CARCINOMA OF THE BREAST G. Stephen Brown, M.D. University of Vermont, College of Medicine; Medical Center Hospital of Vermont, Burlington, Vermont
Confusion in the minds of physicians and lay people as well into the optimal treatment of localized adenocarcinoma of the breast has led to an 45
(30)
THE TREATMENT OF INFLAMMATORY BREAST CARCINOMA BY RADIATION Ann M. Chu, M.D., Dept. of Radiation Medicine, Massachusetts General Hospital, Boston, Mass. William Wood, M.D., Dept. of Surgery, Massachusetts General Hospital , Boston, Mass. Joanne Doucette, B.A., Dept. of Radiation Medicine, Massachusetts General Hospital, Boston, Mass.
From January 1958 through December, 1975, 47 patients with clinical inflammatory breast carcinoma were treated with radiation at the Massachusetts General Hospital. Study includes only those patients who had cliniForty cally local disease confined to the breast and peripheral lymphatics. patients are dead of their disease indicative of the fulminating nature of this tumor. The median survival is 17 months (range 1 month to 8 years, 9 months). Twenty-eight of 47 patients developed local recurrence within the irradiated breast. There does appear to be a definite correlation between dose delivered and local control in this study. An analysis of local recurrence rate as a function of dose (TDF), dosimetry, field arrangements and equipment used will be analyzed. The prognosticating role of extent of erythema, presence or absence of axillary or supraclavicular lymph nodes on survival will be correlated. The effect of hormonal ablative procedures, hormonal manipulation or chemotherapy will be discussed. As survival is determined by high instance of metastatic disease, the combination of effective local treatment and adjuvant multi-agent chemotherapy may hold promise for improving the poor survival seen in this group of patients. Recommendations for an altered radiation regimen, e.g. ultrafractionation will be proposed.
(31) PRIMARY IRRADIATION THERAPY AS M4NAGEMENT FOR STAGE I AND STAGE II CARCINOMA OF THE BREAST G. Stephen Brown, M.D. University of Vermont, College of Medicine; Medical Center Hospital of Vermont, Burlington, Vermont
Confusion in the minds of physicians and lay people as well into the optimal treatment of localized adenocarcinoma of the breast has led to an 45